Dermata Therapeutics Announces Positive Results for Tome Foundational Treatment

SAN DIEGO, October 15, 2026 /CourierPR/ -- Dermata Therapeutics, a science-driven leader in dermatologic solutions, has announced positive topline results from a recently completed cosmetic clinical study evaluating its Tome Foundational Treatment. The study, which involved 31 participants, demonstrated significant improvements in skin appearance after just one treatment. Over 71% of study participants were graded as having overall improvements in their skin after only one treatment. Additionally, 93% of participants agreed that Tome Foundational Treatment was comparable to a professional in-office procedure, and 90% found it more noticeable than other products.

The clinical study consisted of 31 participants in an open-label study of Tome Foundational Treatment. Participants applied Tome Foundational Treatment one time per week for four weeks and were evaluated by an investigator at multiple timepoints throughout the study on endpoints including fine lines, hyperpigmentation, dark spots, smoothness, firmness, radiance, and overall appearance. Participants also completed self-evaluations after four treatments. The study findings include:

- Over 71% of study participants were graded as having overall improvements in their skin after only one treatment. - 93% of participants agreed that Tome Foundational Treatment was comparable to a professional in-office procedure. - 90% of participants agreed they saw more noticeable results compared with other products. - Tome Foundational Treatment was well-tolerated by participants, with no treatment-related adverse events reported.

Gerry Proehl, Dermata's Chairman, President, and Chief Executive Officer, expressed enthusiasm about the results.

Tome Foundational Treatment is now available for purchase at Tome Skincare website either as a one-time purchase of four weekly treatments or through a subscription program at a discounted price. The treatment is powered by Bioneedle™, a hero ingredient consisting of 100% freshwater sponge, which the company wild harvests and minimally processes into a fine, purified powder. Designed to be an easy addition to an existing skincare routine, Tome Foundational Treatment is intended to renew the appearance of the skin and improve the tone and texture of the user's skin over time.

Dermata Therapeutics is a science-driven leader in dermatologic solutions focused on the development and commercialization of both direct-to-consumer and professional skincare solutions. The company leverages its experience in clinical dermatology and its Bioneedle technology to develop differentiated skincare products designed to address a variety of consumer skincare needs. Dermata's first commercial product, Tome Foundational Treatment, is now available, and the company plans to introduce additional innovations in the future.

Forward-looking statements in this press release are subject to known and unknown risks, uncertainties, assumptions, and other factors, including the potential market acceptance of Tome Foundational Treatment and the benefits of any clinical data. These statements are based on the company's current beliefs and expectations and are qualified by the cautionary statements in the press release.